@article {d \textquoteright}Ancona1902259，作者= {d{textquoteright}Ancona, Gr{inne和Kavanagh, Joanne和Roxas, Cris和Green, Linda和Fernandes, Mariana和Thomson, Louise和Dhariwal, Jaideep和Nanzer, Alexandra M.和Jackson, David J.和Kent, Brian d .。},标题={坚持吸入糖皮质激素和临床结果mepolizumab治疗严重哮喘},体积= {55}= {5},elocation-id = {1902259} = {2020}, doi ={10.1183/13993003.02259 -2019},出版商={欧洲呼吸学会},文摘={介绍吸入激素(ICS)实现疾病控制大多数哮喘病人,尽管坚持规定ICS往往是穷人。188bet官网地址严重嗜酸性粒细胞性哮喘患者可能需要口服糖皮质激素(OCS)和/或生物制剂，如美波利单抗。目前尚不清楚ICS的依从性是否改变或改变了对生物疗法的临床反应。方法我们研究了完成1年mepolizumab治疗的ocs依赖性严重嗜酸性粒细胞性哮喘患者的ICS依从性和临床结果。计算了生物制剂推出前一年及推出后一年的综合药物持有比率(按处方发出的综合药物剂量/预期数量)。良好的依从性定义为MPR \>0.75，中间0.74{\textendash}0.51，差的\<0.5。我们检查了12个月生物治疗后的结果，包括OCS减少和年化恶化率(AER)，并根据服用mepolizumab的ICS进行分层。结果在109名开始mepolizumab治疗的患者中，91名完成12个月治疗的患者被纳入最终分析。接受mepolizumab治疗时，68% \%的ICS依从性良好，16 (18\%)ICS依从性较差。在队列中ICS的使用保持相似(MPR 0.81{\textpm}0.32)和mepolizumab治疗期间(0.82{\textpm}0.32; p=0.78). Patients with good adherence had greater reductions in OCS dose (median (interquartile range) OCS reduction 100 (74{\textendash}100)\% versus 60 (27{\textendash}100)\%; p=0.031) and exacerbations (AER change -2.1{\textpm}3.1 versus 0.3{\textpm}2.5; p=0.011) than those with poor adherence. Good ICS adherence predicted the likelihood of stopping maintenance OCS (adjusted OR 3.19, 95\% CI 1.02{\textendash}9.94; p=0.045).Conclusion ICS nonadherence is common in severe eosinophilic asthma patients receiving mepolizumab, and is associated with a lesser reduction in OCS requirements and AER.Poor adherence to ICS is common in severe asthma patients receiving mepolizumab, and is associated with increased oral corticosteroid exposure and exacerbation risk http://bit.ly/2v9hdAi}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/55/5/1902259}, eprint = {//www.qdcxjkg.com/content/55/5/1902259.full.pdf}, journal = {European Respiratory Journal} }